Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria - Impact of metformin treatment

Annals of Agricultural and Environmental Medicine

Volumn 20, Issue 3, 2013, Pages 528-532

  Nawrocka Rutkowska, Jolanta ^a   Ciećwiez, Sylwester ^a   Marciniak, Aleksandra ^a   Brodowska, Agnieszka ^a   Wiśniewska, Berenika ^a   Kotlega, Dariusz ^a   Starczewski, Andrzej ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

HOMA IR; Insulin resistance; Metformin; OGTT; Polycystic ovary syndrome

Indexed keywords

GLUCOSE; INSULIN; METFORMIN;

ARTICLE; BODY MASS; CONTROLLED STUDY; EVENING DOSAGE; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MORNING DOSAGE; OVARY POLYCYSTIC DISEASE; PATIENT ASSESSMENT; PREVALENCE; WAIST HIP RATIO;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; POLAND; POLYCYSTIC OVARY SYNDROME; WAIST-HIP RATIO;

EID: 84884366662     PISSN: 12321966     EISSN: 18982263     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States; a prospective study. J Clin Endocrinol Metab. 1998; 83: 3078-3082.
2. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008; 23: 462-477.
3. Radomski D, Orzechowska A, Barcz E. Wspołczesne koncepcje etiopatogenezy zespołu policystycznych jajnikow. Ginekol Pol. 2007; 78: 393-399.
4. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88: 5957-5962.
5. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006; 12: 324-332.
6. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998; 83: 2001-2005.
7. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935; 29: 181-191.
8. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; 8469-8470: 1375-1379.
9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81: 19-25.
10. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89: 2745-2749.
11. Skałba P. Zespoł policystycznych jajnikow. In: Skałba P, editor. Endokrynologia ginekologiczna. Warszawa, PZWL, 1998. p. 289-298.
12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18: 774-800.
13. Laven JSE, Mulders AGMGJ, van Santbrink, EJP, Eijkemans, MJC, Fauser, BCJM. PCOS: backgrounds, evidence and problems in diagnosing the syndrome. In: Slager E, Fauser B, van Geijn H, Brolmann H, Vervest H, editors. Gynaecology, obstetrics, and reproductive medicine in daily practice, Proceedings of the 15th Congress of Gynaecology, Obstetrics and Reproductive Medicine. International Congress Series 2005; 1279: 10-15.
14. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174.
15. Bigos A, Pałkowska E, Rosołowska-Huszcz D. Effect of artificial and natural sweeteners on glucose and insulin in plasma of rats. JPCCR 2012; 6(2): 93-97.
16. Jakimiuk A, Czajkowski K. Brak owulacji i jajniki policystyczne. In: Speroff L, Fritz M, editors. Kliniczna endokrynologia ginekologiczna i niepłodność. Warszawa, Medipage, 2007. p 533-573.
17. Stra{ogonek}czkowski M, Nikołajuk A, Dzienis-Stra{ogonek}czkowska A. Metody pomiaru insulinooporności in vivo. In: Kinalska I, editor. Patofizjologia i naste{ogonek}pstwa kliniczne insulinooporności. Warszawa, WIG-Press, 2005: p. 215-217.
18. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003; 14: 365-370.
19. Kalme T, Koistinen H, Loukovaara M, Koistinen R, Leinonen PJ. Comparative studies on the regulation of insulin-like growth factorbinding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells. Steroid Biochem Mol Biol. 2003; 86: 197-200.
20. Castracane VD, Kauffman RP. Assessing insulin sensitivity. Contemporary OB/GYN 2003; 48(1): 30-35.
21. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome-a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007; 92: 4546-4556.
22. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994; 43: 647-654.
23. Kołodziejczyk B, Dule{ogonek}ba AJ, Spaczyński RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000; 73: 1149-1154.
24. Gupta S, Chen D, O'Flynn O'Brien K, et al. Adolescent polycystic ovary syndrome: pathophysiology and implications of the disease. Arch Med Sci. 2009; 5(1A): S115-S131.
25. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007; 92: 2500-2505.
26. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004; 82: 661-665.
27. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006; 20: 193-205.
28. Landay M, Huang A, Azziz R Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril. 2009; 92: 643-647.
29. Acien P, Quereda F, Matallin P, Villarroya E, Lopez-Fernandez JA, Acien M, Mauri M, Alfayate R. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999; 72: 32-40.
30. Balen A, Rajkowha M. Polycystic ovary syndrome-a systemic disorder? Best Pract Res Clin Obstet Gynaecol. 2003; 17: 263-274.
31. Saxena P, Prakash A, Nigam A. Efficacy of 2-hour post glucose insulin levels in predicting insulin resistance in polycystic ovarian syndrome with infertility. J Hum Reprod Sci. 2011; 4: 20-22.
32. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab. 2007; 18: 273-279.
33. Santana LF, de Sa MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol. 2004; 19: 88-96.
34. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005; 83: 1454-1460.
35. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998; 83: 2694-2698.
36. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95: 2038-2049.
37. Abbas M, Gannon M. The use of metformin as first line treatment in polycystic ovary syndrome. Ir Med J. 2008; 101: 51-53.
38. Gupta S, Metterle L, Thakkar P, Surti N, Chandra A, Agarwal A. Ovulation induction in polycystic ovary syndrome. Arch Med Sci. 2009; 5(1A): 132-142.